This antibody is a CTLA-4-specific agonistic monoclonal antibody which may stimulate of CTLA-4 and may be used in the treatment of a disease selected from the group consisting of rheumatoid arthritis, type I diabetes, multiple sclerosis, systemic lupus erythematosus, psoriasis, ulcerative Ulerosa, Crohn's disease and so on.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-067 | Anti-Human CTLA4 Recombinant Antibody (Ipilimumab) | WB, FuncS, IF, Neut, ELISA, FC, IP | IgG1 - kappa |
TAB-206 | Anti-Human CTLA4 Recombinant Antibody (Ticilimumab (Tremelimumab)) | WB, IF, IP, Neut, FuncS, ELISA, FC | IgG2 |
There are currently no Customer reviews or questions for TAB-083MZ-F(E). Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.